These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. Ginsberg HN J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700 [TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trials and recent patterns in the use of statins. Wang TJ; Stafford RS; Ausiello JC; Chaisson CE Am Heart J; 2001 Jun; 141(6):957-63. PubMed ID: 11376310 [TBL] [Abstract][Full Text] [Related]
8. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Marrs JC; Saseen JJ Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359 [TBL] [Abstract][Full Text] [Related]
9. Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin. Trapani L; Segatto M; Simeoni V; Balducci V; Dhawan A; Parmar VS; Prasad AK; Saso L; Incerpi S; Pallottini V Biochimie; 2011 Jul; 93(7):1165-71. PubMed ID: 21530605 [TBL] [Abstract][Full Text] [Related]
10. Lipid lowering therapy in atherosclerosis. Aikawa M; Libby P Semin Vasc Med; 2004 Nov; 4(4):357-66. PubMed ID: 15861316 [TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Ramcharan AS; Van Stralen KJ; Snoep JD; Mantel-Teeuwisse AK; Rosendaal FR; Doggen CJ J Thromb Haemost; 2009 Apr; 7(4):514-20. PubMed ID: 19036068 [TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and the statins treatment. Dima A; Marinescu AG; Dima AC Rom J Intern Med; 2012; 50(1):19-25. PubMed ID: 22788090 [TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448 [TBL] [Abstract][Full Text] [Related]
14. The dyslipidemia of chronic renal disease: effects of statin therapy. Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911 [TBL] [Abstract][Full Text] [Related]
15. Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation? Neal DA; Alexander GJ Liver Transpl; 2001 Dec; 7(12):1009-14. PubMed ID: 11753902 [TBL] [Abstract][Full Text] [Related]
16. Hypotensive effects of statins. A place for hydrogen sulfide in the puzzle? Wiliński B; Wiliński J; Somogyi E Folia Med Cracov; 2011; 51(1-4):37-43. PubMed ID: 22891536 [TBL] [Abstract][Full Text] [Related]
17. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Moonis M; Fisher M Expert Rev Neurother; 2004 Mar; 4(2):241-7. PubMed ID: 15853565 [TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Marzilli M Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728 [TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitors and the kidney. Campese VM; Park J Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867 [TBL] [Abstract][Full Text] [Related]
20. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge. Chen YW; Lai HW; Wang TD Acta Neurol Taiwan; 2007 Sep; 16(3):163-7. PubMed ID: 17966956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]